MAVS and systemic lupus erythematosus: Another study investigated the aggregate forming capacity of MAVS in the PBMCs of systemic lupus erythematosus (SLE) patients, the prion-like aggregation of which leads to enhanced type I IFN signaling that consequently fuels autoimmunity [84].